Table 1.
Example of schizo triplets in the interface of human receptor heteromers.
| Receptor heteromer | Reference | Ser-Val-Ser (SVS) | Gly-Leu-Leu (GLL) | Val-Ser-Thr (VST) | Leu-Tyr-Ser (LYS) | Leu-Pro-Phe (LPF) | Ser-Leu-Ala (SLA) |
|---|---|---|---|---|---|---|---|
| GABAB1–GABAB2 | (54–56) | − | # | − | − | − | − |
| GABAB1–CXCR4 | (57) | # | − | # | − | − | − |
| NMDA–CCR2 | Possible heteromer | − | # | − | + | − | − |
| NMDA-interleukin 1 receptor type II (IL1R2) | Possible heteromer | # | − | − | − | − | − |
| NMDA–CXCR4 | Possible heteromer | + | − | # | + | − | − |
| MOP–DOP | (58) | − | − | − | # | # | − |
| CCR2–CXCR4 | (59) | − | − | − | # | − | − |
| DOP–CXCR4 | (60) | − | − | − | # | # | − |
| 5HT1A–5HT1B | (61) | − | − | − | − | # | # |
| 5HT1A–5HT7 | (62) | − | − | − | − | # | # |
| ADRA2A–ADRA2B | (63) | − | − | − | − | − | # |
| ADRB2–ADRB3 | (64) | − | − | − | − | # | # |
| D2–CCR2 | Possible heteromer | − | − | − | # | − | − |
| D2–IL1R2 | Possible heteromer | − | − | − | − | # | # |
| D2–CXCR4 | Possible heteromer | − | − | − | # | # | − |
#, yes in both receptors and may mediate their interaction; +, yes in both receptors; −, no in any receptor.
Location: ec, extracellular; ic, intracellular; TM, transmembrane; SVS—ic GABAB1 # CXCR4; ec NR2A,B,D # IL1R2(N-terminal); GLL—TM GABAB1 # GABAB2; ic NR2A # CCR2(C-tail); VST—ic GABAB1 # CXCR4 (C-tail), NR2A # CXCR4(C-tail), NR1-1,4,5(C-tail) # CXCR4(C-tail); LYS—TM MOP, DOP, CXCR4, D2; LPF—TM MOP, DOP, 5HT1A,B, 5HT7; TM CXCR4 # D2(TM’ec); ec IL1R2 # D2(TM’ec); SLA—TM 5HT1A,B, 5HT7, ADRA2A,B, ADRB2,3; TM IL1R2 # D2. The highlighted text in red color represent the new postulated heteroreceptor complexes based on the Triplet Puzzle Theory